GSK’s blood cancer drug has reached a key goal in a late-stage trial after a series of setbacks.

The results are a major boost for the pharma giant.

The trial found that Blenrep, when combined with existing drug bortezomib plus steroid dexamethasone, extended the time before relapsed or refractory multiple myeloma progressed, or those suffering from the disease died.

The disease is the third most common type of blood cancer which is considered difficult to treat. 

And last year, Blenrep was pulled from US markets after it failed a separate late-stage study designed to show it was better than an existing treatment on the market.

Trial success: GSK’s blood cancer drug Blenrep has reached a key goal in a late-stage trial after a series of setbacks

Trial success: GSK’s blood cancer drug Blenrep has reached a key goal in a late-stage trial after a series of setbacks

Trial success: GSK’s blood cancer drug Blenrep has reached a key goal in a late-stage trial after a series of setbacks

In September, the EU’s drug regulator also recommended against renewing the conditional marketing authorisation for Blenrep, in a setback to the key oncology unit that GSK has been looking to strengthen.

A move to bring the drug back to the market or expand its usage following the results of the latest study would boost for the company. 

The drug belongs to a promising category of treatments called antibody-drug conjugates, which are engineered antibodies that bind to tumour cells and then release cell-killing chemicals.

A ‘strong and clinically meaningful overall survival trend was also observed’, GSK added.

Blenrep, which was the second-largest contributor to GSK’s oncology business in 2022, has made about £30million of sales so far this year.

#fiveDealsWidget .dealItemTitle#mobile {display:none} #fiveDealsWidget {display:block; float:left; clear:both; max-width:636px; margin:0; padding:0; line-height:120%; font-size:12px} #fiveDealsWidget div, #fiveDealsWidget a {margin:0; padding:0; line-height:120%; text-decoration: none; font-family:Arial, Helvetica ,sans-serif} #fiveDealsWidget .widgetTitleBox {display:block; float:left; width:100%; background-color:#af1e1e; } #fiveDealsWidget .widgetTitle {color:#fff; text-transform: uppercase; font-size:18px; font-weight:bold; margin:6px 10px 4px 10px; } #fiveDealsWidget a.dealItem {float:left; display:block; width:124px; margin-right:4px; margin-top:5px; background-color: #e3e3e3; min-height:200px;} #fiveDealsWidget a.dealItem#last {margin-right:0} #fiveDealsWidget .dealItemTitle {display:block; margin:10px 5px; color:#000; font-weight:bold} #fiveDealsWidget .dealItemImage, #fiveDealsWidget .dealItemImage img {float:left; display:block; margin:0; padding:0} #fiveDealsWidget .dealItemImage {border:1px solid #ccc} #fiveDealsWidget .dealItemImage img {width:100%; height:auto} #fiveDealsWidget .dealItemdesc {float:left; display:block; color:#004db3; font-weight:bold; margin:5px;} #fiveDealsWidget .dealItemRate {float:left; display:block; color:#000; margin:5px} #fiveDealsWidget .dealFooter {display:block; float:left; width:100%; margin-top:5px; background-color:#e3e3e3 } #fiveDealsWidget .footerText {font-size:10px; margin:10px 10px 10px 10px;} @media (max-width: 635px) { #fiveDealsWidget a.dealItem {width:19%; margin-right:1%} #fiveDealsWidget a.dealItem#last {width:20%} } @media (max-width: 560px) { #fiveDealsWidget #desktop {display:none;} #fiveDealsWidget #mobile {display:block!important} #fiveDealsWidget a.dealItem {background-color: #fff; height:auto; min-height:auto} #fiveDealsWidget a.dealItem {border-bottom:1px solid #ececec; margin-bottom:5px; padding-bottom:10px} #fiveDealsWidget a.dealItem#last {border-bottom:0px solid #ececec; margin-bottom:5px; padding-bottom:0px} #fiveDealsWidget a.dealItem, #fiveDealsWidget a.dealItem#last {width:100%} #fiveDealsWidget .dealItemContent, #fiveDealsWidget .dealItemImage {float:left; display:inline-block} #fiveDealsWidget .dealItemImage {width:35%; margin-right:1%} #fiveDealsWidget .dealItemContent {width:63%} #fiveDealsWidget .dealItemTitle {margin: 0px 5px 5px; font-size:16px} #fiveDealsWidget .dealItemContent .dealItemdesc, #fiveDealsWidget .dealItemContent .dealItemRate {clear:both} }

This post first appeared on Dailymail.co.uk

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

OpenAI in turmoil as staff call for ousted chief exec to return and board to go

The future of OpenAI hangs in the balance as the board opens…

The five steps to take now so your radiators heat up in minutes – and it can slash energy bills

CHRISTMAS is just around the corner and it may be the time…

A ‘glitch’ in ULEZ rules meant my new car would cost an extra £3,250 a year to drive – are you affected too?

A SELF-employed Londoner spent £2,500 on a used car on the basis…

Offices and other commercial premises to share a £481m business rates rebate

Offices and commercial premises have been given a 25 per cent business…